Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1089MR)

This product GTTS-WQ1089MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1089MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7120MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ12129MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ1405MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ10938MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ5676MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ4074MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ838MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ7867MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW